TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04887714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mask
Description: Mask wearing
Study: NCT05508191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO₂ Laser
Description: Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
Study: NCT05935852

Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses

Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses

Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses

Intervention type: DEVICE
Group type: OTHER
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
Study: NCT04974346

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation
Description: The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
Study: NCT05505214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial decolonization
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% cream
Description: Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacterial decolonization and Mometasone furoate 0.1% cream
Description: Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
Study: NCT05615012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Specified dose on specified days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days
Study: NCT05109650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6026
Description: IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: Ⅳ infusions
Study: NCT04974346

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic definitive concurrent chemoradiation
Description: Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
Study: NCT06412705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction, guided bone regeneration and dental implant
Description: The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
Study: NCT06108336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS during sequence-demanding task
Description: TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS during sequence-demanding task
Description: TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No TMS during sequence-demanding task
Description: TMS is not administered during the execution of sequence-demanding task.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TMS during sequence-demanding task
Description: TMS is not administered during the execution of sequence-demanding task.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS during non-sequence-demanding task
Description: TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TMS during non-sequence-demanding task
Description: TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
Study: NCT06241664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEYE-DS Software
Description: An Artificial Intelligence (AI) software device to be used as a diagnostic tool to assist healthcare providers in screening for diabetic retinopathy (DR) using digital funduscopic images. The device automatically detects more than mild diabetic retinopathy (mtmDR) in adults diagnosed with diabetes who have not been previously diagnosed with DR.
Study: NCT05039619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Study: NCT04890938

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sputum-guided management and comprehensive care management
Description: Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
Study: NCT05039619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
Study: NCT06476769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blow bottle technique
Description: There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: percussion
Description: Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
Study: NCT06263946

Intervention type: DEVICE
Group type: OTHER
Intervention: Essilor® Stellest® spectacle lenses
Description: patients will be asked to wear Essilor® Stellest® spectacle lenses more than 12 hours per day for 24 months.
Study: NCT06489353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-watching
Description: Participants will watch age-appropriate and engaging videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blowing Pinwheels
Description: Participants will blow pinwheels during the venipuncture procedure
Study: NCT04745156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS System Implantation
Description: Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
Study: NCT05166590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Sleep Deprivation
Study: NCT05039619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen/paracetamol
Description: Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine hydrochloride (HCl)
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Study: NCT05764733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonate
Description: Medicine used to treat bone problems, called osteopenia or osteoporosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonate
Description: Medicine used to treat bone problems, called osteopenia or osteoporosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training/Bone-Loading Exercise
Description: Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training/Bone-Loading Exercise
Description: Exercise in small groups three days per week under the supervision of exercise physiologists. Heart rate and blood pressure will be measured before and after each session and participants will warm-up by walking or cycling for five minutes at a slow pace. All RT exercises will be conducted on machines which accommodate different body sizes and allow small increments in resistance, both important considerations for low functioning older adults with obesity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules identical to the active alendronate capsules without any active ingredients with the same dosing and follow up as BIS treatment group.
Study: NCT05493527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive high frequency oscillatory ventilation
Description: A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive positive pressure ventilation
Description: NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter.
Study: NCT06108336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No TMS during non-sequence-demanding task
Description: TMS is not administered during the execution of non-sequence-demanding task

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No TMS during non-sequence-demanding task
Description: TMS is not administered during the execution of non-sequence-demanding task
Study: NCT05263986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1.
Study: NCT06421636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7999
Description: Administered subcutaneous (SC)
Study: NCT05097651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert sesame seed oil
Description: Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.